A study of ERG, PTEN, and ki-67 in a phase III trial assessing docetaxel and estramustine in high-risk localized prostate cancer (GETUG 12).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 5063-5063 ◽  
Author(s):  
Shanna Rajpar ◽  
Philippe Vielh ◽  
Agnes Laplanche ◽  
Francois Lesaunier ◽  
Remy Delva ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Phase Iii ◽  
Localized Prostate Cancer ◽  
Ki 67 ◽  
Phase Iii Trial

scholarly journals PD-0046: Outcome according to pelvic radiotherapy in the GETUG 12 phase III trial for high-risk localized prostate cancer

2015 ◽  
Vol 115 ◽  
pp. S22
Author(s):  
P. Blanchard ◽  
L. Faivre ◽  
F. Lesaunier ◽  
N. Salem ◽  
N. Mesgouez-Nebout ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Phase Iii ◽  
Localized Prostate Cancer ◽  
Pelvic Radiotherapy ◽  
Phase Iii Trial

Long-term tolerance of neoadjuvant docetaxel/estramustine chemotherapy in patients with high-risk localized prostate cancer treated at IGR in the GETUG 12 phase III trial.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 168-168
Author(s):  
Pierre-Olivier Bosset ◽  
Laurence Albiges ◽  
Agnes Laplanche ◽  
Christophe Massard ◽  
Yohann Loriot ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Sexual Function ◽  
Serum Testosterone ◽  
Phase Iii ◽  
Localized Prostate Cancer ◽  
Cardiac Complications ◽  
Phase Iii Trial ◽  
Long Term Impact

168 Background: The GETUG 12 phase III trial tested the adjunction of docetaxel-estramustine to standard treatment in 413 patients with high-risk prostate cancer (Eur J Cancer 2012, 48: 209-17). Patients in both arms received androgen deprivation therapy (ADT) for 3 years plus local treatment (radiotherapy: 87%, median dose: 74 Gy). Pts in the chemotherapy arm also received 4 cycles of docetaxel 70mg/m2 /3weeks + estramustine 10 mg/kg/d d1-5, repeated every 3 weeks. Immediate tolerance was acceptable with only 2% of febrile neutropenia and no toxic deaths. As the long-term impact of chemotherapy in this setting is unknown, long-term side effect assessment was undertaken in pts from GETUG 12 who were treated at the Institut Gustave Roussy (n=81). Methods: After pts had completed the planned 3 years of ADT, they were followed-up every 6 months. Data on weight, sexual function, serum testosterone, and cardiac complications were obtained prospectively, in parallel with efficacy data. Pts requiring salvage therapy for cancer progression were censored in this analysis. Results: The median follow-up is 71.6 months (range: 36- 108 months). The main long-term side effects are listed in the table below. 4 (4.9%) and 1(1.2%) cardiovascular events occurred in the ADT and the ADT + chemotherapy arm, respectively. Conclusions: Docetaxel-estramustine chemotherapy had no adverse long-term impact on serum testosterone, weight, and sexual function in patients with high-risk localized prostate cancer treated with ADT and radiotherapy. [Table: see text]

Long-term versus short-term androgen deprivation combined with high-dose radiotherapy for localized prostate cancer: A Spanish multicenter phase III trial.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e15036-e15036 ◽  
Author(s):  
A. Zapatero ◽  
A. Guerrero ◽  
X. Maldonado ◽  
A. Alvarez ◽  
C. González San Segundo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation ◽  
Phase Iii ◽  
Localized Prostate Cancer ◽  
High Dose ◽  
Short Term ◽  
Phase Iii Trial ◽  
Multicenter Phase

Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 5005-5005 ◽  
Author(s):  
Karim Fizazi ◽  
Agnes Laplanche ◽  
Francois Lesaunier ◽  
Remy Delva ◽  
Gwenaelle Gravis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
High Risk Prostate Cancer ◽  
Tumor Group ◽  
Risk Prostate Cancer

A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. TPS5098-TPS5098 ◽  
Author(s):  
Karim Fizazi ◽  
Muriel Habibian ◽  
Agnes Laplanche ◽  
Herve Baumert ◽  
Riccardo Valdagni ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Factorial Design ◽  
Phase Iii ◽  
Localized Prostate Cancer ◽  
Pelvic Radiotherapy
Sign in / Sign up

Export Citation Format

Share Document